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Bacterial Lysis Liberates the Neutrophil Migration Suppressor YbcL
from the Periplasm of Uropathogenic Escherichia coli
Megan E. Lau,a* Elizabeth S. Danka,a Kristin M. Tiemann,a David A. Hunstada,b
Departments of Pediatricsa and Molecular Microbiology,b Washington University School of Medicine, St. Louis, Missouri, USA

U

rinary tract infections (UTIs), which are among the most
common bacterial infections in humans, are caused chiefly by
uropathogenic Escherichia coli (UPEC) (1). The economic and
societal burdens associated with UTIs are substantial; in the
United States alone, UTIs result in approximately $4 billion in
direct and indirect costs annually, including millions of physician
visits and antibiotic prescriptions (2, 3). While antibiotics typically help to resolve acute, uncomplicated UTIs, UPEC strains are
acquiring resistance to commonly used antibiotic classes at an
alarming rate (4). Additionally, complicated and recurrent UTIs
plague a notable subset of the population, despite antibiotic treatment and apparent resolution of prior infections (5). To address
these ongoing challenges, it is imperative to understand the mechanisms by which UPEC causes disease in the urinary tract.
The establishment of a UTI represents a critical point in the
UPEC infectious cycle. To facilitate colonization of the bladder,
UPEC dampens the innate immune response (6), characterized by
the production of cytokines and chemokines and the recruitment
of leukocytes, primarily polymorphonuclear leukocytes (PMN) or
neutrophils, from the periphery to the bladder lumen (7, 8). One
strategy for suppressing acute inflammation relies on the activity
of UPEC-encoded YbcL, a periplasmic protein that inhibits transuroepithelial PMN migration in an in vitro model and during in
vivo murine cystitis (9). The delayed arrival of PMN to the bladder
provides an interval, free of phagocytic pressure, during which
UPEC can accomplish invasion of the uroepithelium, a step that is
essential for the propagation of infection. Conservation of YbcL
homologs among UPEC isolates associated with various disease
manifestations suggests that the suppressive activity of this protein is important for colonization of the urinary tract (9). Nonpathogenic E. coli strain MG1655 also encodes a YbcL variant
(denoted YbcLMG), though a single amino acid substitution
(T78V) in this variant abrogates its effect on PMN migration (9).
However, the suppressive activity of UPEC YbcL can be conferred
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on MG1655 through episomal expression of YbcLUTI, the variant
encoded by cystitis isolate UTI89, or by exogenous addition of
purified YbcLUTI to the bacterial inoculum at concentrations as
low as 8 pM (9). Lastly, liberation of YbcLUTI from the periplasm
is required for suppression of transuroepithelial PMN migration
(9), though the mechanism by which YbcLUTI is released and the
site of action of YbcLUTI are unclear.
Aside from the type V secretion systems (T5SS), few proteins
secreted from the periplasm and their corresponding modes of
secretion have been well characterized in UPEC. Outer membrane
vesicles (OMVs) have been shown to deliver cytotoxic necrotizing
factor 1 (Cnf1), a UPEC toxin, to the extracellular environment
and eukaryotic cells (10–12). However, OMVs have not been extensively investigated in the context of UPEC infection, and no
other UPEC effectors delivered by OMVs have been identified.
Additionally, the type II secretion system (T2SS) and type IV pilus
(T4P) encoded by UPEC appear to contribute to pathogenesis in
the urinary tract (13), though periplasmic substrates of these systems that are important for pathogenesis have yet to be identified.
Though far less common, bacterial death can also serve as a mechanism for release of intracellular proteins into the extracellular
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Uropathogenic Escherichia coli (UPEC) modulates aspects of the innate immune response during urinary tract infection to facilitate bacterial invasion of the bladder epithelium, a requirement for the propagation of infection. For example, UPEC-encoded
YbcL suppresses the traversal of bladder epithelia by neutrophils in both an in vitro model and an in vivo murine cystitis model.
The suppressive activity of YbcL requires liberation from the bacterial periplasm, though the mechanism of release is undefined.
Here we present findings on the site of action of YbcL and demonstrate a novel mode of secretion for a UPEC exoprotein. Suppression of neutrophil migration by purified YbcLUTI, encoded by cystitis isolate UTI89, required the presence of a uroepithelial
layer; YbcLUTI did not inhibit neutrophil chemotaxis directly. YbcLUTI was released to a greater extent during UPEC infection of
uroepithelial cells than during that of neutrophils. Release of YbcLUTI was maximal when UPEC and bladder epithelial cells were
in close proximity. Established modes of secretion, including outer membrane vesicles, the type II secretion system, and the type
IV pilus, were dispensable for YbcLUTI release from UPEC. Instead, YbcLUTI was liberated during bacterial death, which was augmented upon exposure to bladder epithelial cells, as confirmed by detection of bacterial cytoplasmic proteins and DNA in the
supernatant and enumeration of bacteria with compromised membranes. As YbcLUTI acts on the uroepithelium to attenuate
neutrophil migration, this mode of release may represent a type of altruistic cooperation within a UPEC population during colonization of the urinary tract.

Lau et al.

MATERIALS AND METHODS
Bacterial strains and culture. E. coli was grown statically in Luria-Bertani
(LB) broth for 18 h at 37°C. Ampicillin, chloramphenicol, or isopropyl
␤-D-1-thiogalactopyranoside (IPTG) was added at 100 g/ml, 20 g/ml,
or 100 M, respectively, unless otherwise indicated. MG1655 is a K-12
laboratory strain of E. coli (16), and UTI89 is a UPEC isolate from a patient
with cystitis (17). UTI89 fimH::kan was a kind gift from S. Hultgren.
UTI89/pcomGFP contains the GFPmut3 gene in pcom100, where green
fluorescent protein (GFP) is constitutively expressed (18). UTI89 ⌬ybcL
was generated by excision of the chloramphenicol resistance cassette from
UTI89 ybcL::cat (9) through introduction of the Flp recombinase-expressing vector pCP20 (19). pYbcLUTI, containing the UTI89 ybcL allele in
pTRC99A (Ampr), was created as previously described (9). UTI89 yheF::
cat was created by linear transformation of UTI89/pKM208 (20) with a
fragment amplified from template plasmid pKD3 (19) using the primers
MEL296 and MEL297 (primer sequences are given in Table S1 in the
supplemental material). UTI89 hofQ::cat was created similarly using
primers MEL300 and MEL301. The deletions were verified by direct sequencing.
To replace the ampicillin resistance cassette in pTRC99A with a chloramphenicol resistance cassette, pTRC99A was amplified using primers
MEL245 and MEL246, and the chloramphenicol resistance cassette was
amplified from template plasmid pKD3 (19) using primers MEL247 and
MEL248. The resulting PCR products were digested with PacI and SpeI
and then ligated. Transformed clones of E. coli Top10 (Invitrogen) were
selected on chloramphenicol plates, and the accuracy of the resulting plasmid, pMEL25, was tested by PCR and restriction enzyme digestion. To
generate a translational fusion between YbcL and the ␤-lactamase variant
TEM-1, the ybcL open reading frame (ORF) was amplified from UTI89
genomic DNA using primers MEL253 and MEL275 and digested with
SacI and NotI. The DNA sequence encoding the mature form of TEM-1
(excluding the signal sequence) was amplified from plasmid pBR322 using primers MEL278 and MEL284, with the reverse primer containing the
FLAG epitope sequence, and digested with NotI and BamHI. The digested
PCR products were ligated into pMEL25 (Chlr) that had been digested
with SacI and BamHI. Transformed clones of E. coli Top10 were selected
on chloramphenicol plates, and the accuracy of the resulting construct
pYbcL::TEM-1 was confirmed by direct sequencing. Expression of the
fusion protein upon IPTG induction was confirmed by Western blotting
of bacterial lysates.
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UTI89 surA::kan was generated as described previously (21). To control expression and monitor localization, a plasmid (denoted pSurA) encoding SurA with a C-terminal hemagglutinin (HA) tag under the control
of an IPTG-inducible promoter was constructed. The surA ORF was amplified from UTI89 genomic DNA using primers JLP253 and JLP254, with
the reverse primer containing the HA epitope sequence, and digested with
XbaI and HindIII. The digested PCR product was ligated into pTRC99A
(Ampr) that had been similarly digested. Transformed clones of Top10
were selected on ampicillin plates, and the accuracy of the resulting construct was confirmed by direct sequencing. The tetracycline resistance
cassette from CLC328 skp::tet (a kind gift of T. Silhavy) was transferred by
P1 phage transduction to UTI89, generating UTI89 skp::tet. As with
pSurA, the skp ORF was amplified from UTI89 genomic DNA using primers MEL243 and MEL244, with the reverse primer containing the FLAG
epitope sequence, and digested with BamHI and XbaI. The digested PCR
product was ligated into pTRC99A (Ampr) that had been similarly digested. Transformed clones of Top10 were selected on ampicillin plates,
and the accuracy of the resulting construct, pSkp, was confirmed by direct
sequencing.
Human PMN isolation and migration. In accordance with a protocol
approved by the Washington University Human Research Protection Office, PMN were isolated from venous blood of healthy adult volunteers
according to previously established protocols (9, 22). Briefly, dextran sedimentation was used to reduce erythrocytes, leukocytes were separated
using a Ficoll density gradient (Ficoll-Paque Plus; GE Healthcare), and
remaining erythrocytes were lysed hypotonically. Purified PMN were resuspended in serum-free RPMI 1640 medium (Gibco) to a concentration
of 107 PMN/ml and used immediately. PMN viability was ⬎99% as assessed by trypan blue exclusion, and purity was ⬎99% as determined by
visualization of nuclear morphology after staining (Hema3; Fisher Scientific).
To evaluate PMN migration, 100 nM N-formyl-Met-Leu-Phe (fMLF)
(Sigma) was added to 0.6 ml RPMI in a 24-well low attachment plate
(Corning). YbcL variants, YbcLUTI and YbcLMG, expressed by UTI89 and
MG1655, respectively, were purified as previously described (9) and
added to the 24-well plate at a final concentration of 225 ng/ml, where
indicated. Transwell inserts (0.33-cm2 polyester membranes with a 3-m
pore size; Corning), either empty and uncoated or bearing confluent 5637
epithelial layers prepared as described previously (9, 22), were added to
each well, and 106 freshly isolated human PMN, prepared as described
above, were applied to the upper reservoir. PMN migration across the
Transwell insert into the lower reservoir was enumerated after 1 h using a
hemacytometer and is shown normalized to 106 input PMN. The mean
and standard error of the mean (SEM) from at least 3 experiments is
shown.
Tissue culture and in vitro infection. Human bladder epithelial cell
lines 5637 (ATCC HTB-9) and T24 (ATCC HTB-4) were cultured in
RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS)
(Sigma). UROtsa cells, derived from the uroepithelium of human ureter
(23), were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
(Sigma) containing 10% FBS. Human lung epithelial cell lines A549 (obtained from A. Hamvas) and HCC827 (ATCC CLR-2868) were grown in
RPMI with 10% FBS. All cell lines were grown and infected at 37°C in a
humidified atmosphere with 5% CO2 and then washed three times with
Dulbecco’s phosphate-buffered saline (DPBS) (Gibco) before use in experiments. All infections were performed in serum-free RPMI or DPBS as
noted below.
To assess localization by Western blotting, 5637 cells or freshly isolated
PMN were infected in RPMI with the indicated strains of E. coli at a
multiplicity of infection (MOI) of 40 bacteria/cell for 1 h unless otherwise
noted. The supernatant was collected, and the epithelial cells were washed
with PBS. Lysis was achieved by addition of 0.1% Triton X-100. The supernatant and cell lysate samples were sterilized using syringe-driven filters (0.22-m pore size; Millipore), and protein was precipitated using
15% trichloroacetic acid (TCA) (Sigma) and then probed by Western
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milieu. In other E. coli pathotypes, Shiga toxin is liberated from
the periplasm and colicin from the cytoplasm during bacteriophage-mediated lysis and quasilysis, respectively (14, 15). However, liberation of UPEC effectors solely through bacterial death
has not been demonstrated. As the mode of release has bearing on
protein stability, delivery, and targeting, elucidating the route by
which YbcLUTI leaves the periplasm may provide insight into its
activity.
In this study, we investigated the site of action and the mode of
release of YbcLUTI during UPEC infection. Suppression of PMN
migration by YbcLUTI required the presence of bladder epithelial
cells. Release of YbcLUTI from the periplasm was augmented when
UPEC was exposed to cultured uroepithelial cells, compared with
exposure to PMN or medium alone; this increase depended on
proximity of UPEC to bladder epithelial cells. Additionally,
YbcLUTI was released from UPEC in soluble form, though the
T2SS and T4P encoded by UTI89 were dispensable for YbcLUTI
release. However, a significant increase in bacterial death, liberating YbcLUTI, was demonstrated upon UPEC exposure to bladder
epithelial cells. Taken together, these results contribute to our
understanding of the site of action of YbcLUTI and describe a novel
mode of delivery for a UPEC exoprotein.

UPEC Lysis Liberates Periplasmic YbcL
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medium, was cleared by centrifugation at 16,000 ⫻ g for 5 min. UTI89/
pYbcL::TEM-1 ⌬ybcL was incubated in the conditioned medium for 1 h
before ␤-lactamase activity in the supernatant was measured as described
above.
Statistical analysis. Statistically significant differences were evaluated
using an unpaired Student t test unless otherwise indicated.
DNA precipitation and PCR. To probe the supernatant for bacterial
DNA, 5637 cells in 15-cm dishes were mock infected or infected with
wild-type UTI89 at an MOI of 40 for 1 h unless otherwise noted. The
supernatant was filter sterilized, sodium acetate and isopropanol were
added to final concentrations of 300 mM and 50%, respectively, and the
supernatant was incubated at 4°C overnight. DNA was pelleted by centrifugation at 11,000 ⫻ g for 30 min, washed with 70% ethanol, air dried, and
then resuspended in 10 mM Tris–1 mM EDTA, pH 8.0. PCR was conducted using equivalent volumes of the precipitated DNA samples as templates, 30 rounds of amplification, and primers MEL173 and MEL174,
complementary to the chromosomal UTI89 ybcL allele. Amplicons were
resolved using 1% agarose gels and visualized after ethidium bromide
staining.
Bacterial viability. To assess bacterial viability, wild-type UTI89 was
incubated in RPMI in the presence or absence of 5637 cells for 1 h. Bacteria in the supernatant were applied to poly-L-lysine-coated coverslips
(BD Biosciences) by centrifugation at 400 ⫻ g for 5 min, fixed with 3%
paraformaldehyde for 30 min, and then stained using the Live/Dead
BacLight bacterial viability kit (Invitrogen) according to the manufacturer’s instructions. Coverslips were mounted onto slides using ProLong
Gold antifade reagent (Invitrogen) and imaged using an epifluorescence
microscope (Zeiss Axioskop 2 MOT Plus). Green (live) and red (dead)
bacteria were enumerated using Volocity 3D image analysis software (Perkin-Elmer). Data are represented as a percentage of total bacteria enumerated, and the mean of 4 replicates is shown. Statistically significant differences in viability were determined using Fisher’s exact test. In additional
experiments to detect bacterial fragments not identified by BacLight staining, bacteria were also incubated with rabbit anti-E. coli (E3500-06; US
Biologicals) or anti-OmpA antiserum, followed by detection with Alexa
Fluor 350-conjugated anti-rabbit IgG secondary antibody (A11046; Life
Technologies).

RESULTS

Suppression of PMN migration by YbcLUTI requires a bladder
epithelial barrier. Given the localization of YbcLUTI to cell lysates
of both bladder epithelial cells and PMN during UPEC infection
(9), we sought to further characterize the site of action of YbcLUTI
by investigating the requirement for bladder epithelial cells during
suppression of PMN migration. We employed an in vitro assay,
analogous to the transuroepithelial PMN migration assay (9, 22),
to quantify PMN migration across empty Transwell inserts with
pores sufficiently small to prevent passive movement of PMN. The
chemoattractant peptide fMLF was placed in the lower reservoir of
a Transwell insert, freshly isolated PMN were applied to the upper
reservoir, and the level of PMN migration across the Transwell
insert into the lower reservoir was quantified after 1 h using a
hemacytometer. In the presence or absence of 5637 bladder epithelial cells on the Transwell inserts, fMLF elicited significantly
more PMN migration than mock treatment (Fig. 1A and 1B, respectively) (P ⬍ 0.005). The addition of purified YbcLUTI to the
lower reservoir significantly reduced the level of PMN elicited by
fMLF when 5637 cells were present on the Transwell insert (Fig.
1A) (P ⬍ 0.05). In agreement with previous findings (9), suppression of transuroepithelial PMN migration was not observed upon
addition of the MG1655 YbcL variant (YbcLMG) (Fig. 1A). In contrast, purified YbcLUTI had no effect on PMN migration when
empty Transwell inserts were used (Fig. 1B), even at a concentra-
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blotting. D-Mannose (2%, wt/vol; Sigma) was added in selected experiments, as noted in Results.
To spatially separate the bacterial inoculum from 5637 cells grown to
confluence in the bottom of a 6-well plate, UTI89/pYbcLUTI ybcL::cat was
applied to 1 ml DPBS in the upper reservoir of a Transwell insert (4.67cm2 polyester membranes with a 0.4-m pore size; Corning), while 2 ml
DPBS was applied to the lower reservoir. After 1 h of incubation, the
supernatants from the upper and lower reservoirs and the cell lysate were
sterilized, TCA precipitated, and probed by Western blotting as described
above.
Protease protection and ultracentrifugation assays. The protease
protection assay is based on previously published protocols (11, 24). To
generate sterile supernatant containing YbcLUTI, 5637 cells in RPMI in
15-cm dishes were infected with UTI89/pYbcLUTI ybcL::cat at an MOI of
40. After 1 h of incubation, the supernatant was filter sterilized and separated into four aliquots. Where indicated, proteinase K (Sigma), Triton
X-100, or phenylmethylsulfonyl fluoride (PMSF) (Sigma), a protease inhibitor, was added to the aliquots at 200 g/ml, 0.1%, or 5 mM, respectively. After incubation at 37°C for 45 min, protein was precipitated from
the reaction mixtures using 15% TCA and then probed by Western blotting. In parallel experiments, sterile supernatant, generated as described
above, was ultracentrifuged at 245,000 ⫻ g for 1 h at 4°C. Protein was
precipitated from the supernatant using 15% TCA, while the ultracentrifuged pellet was resuspended using Laemmli sample buffer. The samples
were probed by Western blotting.
Western blotting. Proteins were separated by SDS-PAGE using 12%
polyacrylamide gels and transferred to a polyvinylidene difluoride
(PVDF) membrane (Millipore). After blocking with 2% nonfat milk plus
2% BSA, blots were probed with mouse anti-FLAG (1:1,000; Sigma), rabbit anti-HA (1:4,000; Invitrogen), rabbit anti-GroEL (1:106; Sigma), or
rabbit anti-GFP (1:4,000; Clontech) antibodies followed by goat antimouse or goat anti-rabbit IgG antibodies (1:2,000; Sigma) and were developed using Tropix CDP-Star (Applied Biosystems). Densitometry
analysis was performed with ImageJ.
␤-Lactamase reporter assays. Cultured epithelial cells in 6-well plates
were infected with UTI89/pYbcL::TEM-1 ⌬ybcL at an MOI of 40 for 1 h
unless otherwise indicated. The supernatant was cleared by centrifugation
at 16,000 ⫻ g for 5 min, and then aliquots were pipetted into a 96-well
plate. CCF2-FA (Invitrogen), a ␤-lactamase substrate consisting of a
cephalosporin core linking a 7-hydroxycoumarin to a fluorescein, was
added at a final concentration of 500 nM. In the presence of ␤-lactamase
activity, the cephalosporin core is cleaved, disrupting fluorescence resonance energy transfer (FRET) between the coumarin and fluorescein molecules and changing the emitted fluorescence from green (520 nm) to blue
(447 nm). The reaction mixtures were incubated in the dark for 1 h at
37°C with shaking before fluorescence (excitation at 409 nm and emission
at 447 nm and 520 nm) was measured using a microtiter plate reader
(Synergy 2; BioTek). Fluorescence is represented as a ratio of 447 nm to
520 nm, and the mean and SEM from at least 3 experiments are shown.
To assess how PMN exposure affects release of YbcL::TEM-1 from the
periplasm, 5637 cells or PMN (isolated as described above) in 15-cm
dishes were infected with UTI89/pYbcL::TEM-1 ⌬ybcL at an MOI of 40.
After 1 h infection, the supernatants were filter sterilized and concentrated
10-fold using centrifugal filter devices (10-kDa cutoff; Millipore). ␤-Lactamase activity in the concentrated supernatants was measured as described above. In selected experiments, a protease inhibitor (Complete
Ultra Mini tablets; Roche) was added to supernatants following collection.
Experiments employing Transwell inserts (0.4-m pore size; Corning) to spatially separate the bacterial inoculum (in this case UTI89/
pYbcL::TEM-1 ⌬ybcL) from 5637 cells were conducted as described
above. After 1 h of incubation, the supernatants in the upper and lower
reservoirs were combined and cleared by centrifugation, and ␤-lactamase
activity was measured. To generate conditioned medium, 5637 cells were
incubated in 1 ml RPMI for 1 h, and then the supernatant, or conditioned
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FIG 1 Bladder epithelial cells are required for suppression of PMN migration
by YbcLUTI. (A and B) PMN were applied to the upper reservoir of either
Transwell inserts bearing confluent 5637 bladder epithelial cell layers (A) or
empty Transwell inserts (B), and migration into the lower reservoir was enumerated after 1 h and is shown normalized to 106 input PMN. fMLF and
purified YbcL variants were included in the lower reservoir, where indicated.
In the presence of 5637 cells on the Transwell inserts, YbcLUTI, but not
YbcLMG, significantly reduced the level of PMN migration elicited by fMLF (A)
(*, P ⬍ 0.05). In contrast, YbcLUTI had no effect on PMN migration in the
absence of 5637 cells (B). (C) 5637 cells were incubated with UTI89/pYbcLUTI
ybcL::cat (bacteria) or 100 ng purified YbcLUTI (protein) for 1 h, and then the
supernatant and 5637 cell lysate were filter sterilized, TCA precipitated, and
probed by Western blotting. YbcLUTI was detected in the supernatant and cell
lysate during UPEC infection but was detected solely in the supernatant when
the inoculum consisted of purified protein.

tion 1,500-fold above the lowest effective dose (9). These observations demonstrate that suppression of PMN migration by YbcLUTI
in this model requires the presence of a bladder epithelial barrier.
To further investigate the site of action of YbcLUTI, we com-
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pared the localization of exogenous purified YbcLUTI with that of
YbcLUTI episomally expressed by UPEC. Cultured 5637 cells in
6-well plates were either infected with UTI89/pYbcLUTI ybcL::cat
or incubated with 100 ng purified YbcLUTI for 1 h. The supernatant and 5637 cell lysate were filter sterilized to remove intact
bacteria, protein was precipitated using 15% TCA, and the samples were probed by Western blotting. Consistent with prior results (9), YbcLUTI was detected in both the supernatant and 5637
cell lysate during UPEC infection (Fig. 1C, bacteria). However,
YbcLUTI was detected only in the supernatant when purified protein was substituted for a live bacterial inoculum (Fig. 1C, protein). Similar results were observed when the experiment was
scaled up to 15-cm dishes, suggesting that the absence of purified
YbcLUTI from the 5637 cell lysate did not reflect insensitivity of the
Western blotting reagents. As purified YbcLUTI suppressed PMN
migration in the transuroepithelial PMN migration assay (9) (Fig.
1A), these data suggest that YbcLUTI functions primarily from an
extracellular location.
YbcLUTI is released into the supernatant in soluble form.
While purified YbcLUTI suppressed transuroepithelial PMN migration in vitro, it was unclear whether YbcLUTI was released from
the periplasm in soluble form during UPEC infection. In addition
to canonical secretion systems such as the T2SS, OMVs have been
implicated in secretion of bacterial effectors (25). To explore the
mode of delivery from the periplasm, we examined the characteristics of extracellular YbcLUTI. Cultured 5637 cells were infected
with UTI89/pYbcLUTI ybcL::cat for 1 h, and the supernatant was
filter sterilized and subjected to protease (proteinase K) treatment
in the presence and absence of detergent (Triton X-100) or protease inhibitor (PMSF). By Western blotting, YbcLUTI was entirely
susceptible to digestion by protease in the absence of detergent,
indicating that YbcLUTI in the supernatant is not contained within
OMVs (Fig. 2A). Similar trends in protease susceptibility were
observed when purified YbcLUTI in RPMI was used in place of the
supernatant from 5637 cell infection (data not shown). Additionally, the concentration of protease used in these experiments did
not compromise OMV integrity in the absence of detergent, as
assessed using purified OMVs (data not shown). To confirm these
observations using an alternative approach, we ultracentrifuged
sterile supernatant, generated by infection of 5637 cells with
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FIG 2 YbcLUTI is released from the bacterial periplasm in soluble form. 5637
cells were infected with UTI89/pYbcLUTI ybcL::cat for 1 h before the supernatant was filter sterilized. (A) Proteinase K, Triton X-100, or PMSF was added to
the sterile supernatant, where indicated, and the reaction mixtures were
incubated at 37°C for 45 min. (B) Alternatively, sterile supernatant (S) was
ultracentrifuged at 245,000 ⫻ g for 1 h at 4°C. Protein was TCA precipitated, when necessary, and probed by Western blotting. YbcLUTI was degraded by proteinase K in the absence of Triton X-100 (A) and was detected
exclusively in the supernatant (UC-S), and not in the pellet (UC-P), after
ultracentrifugation (B).

UPEC Lysis Liberates Periplasmic YbcL

coli K-12. 5637 cells were infected with the indicated strains of E. coli for 1 h.
The supernatant and 5637 cell lysate were filter sterilized, TCA precipitated,
and probed by Western blotting. An equivalent volume of each bacterial inoculum (input) was included to demonstrate similar YbcLUTI expression across
bacterial strains. (A) As seen during infection with UTI89/pYbcLUTI, YbcLUTI
was detected in the supernatant and cell lysate during infection with nonpathogenic E. coli strain MG1655/pYbcLUTI. (B) The levels of YbcLUTI in the
supernatant and cell lysate were unaffected by lack of YheF or HofQ, secretins
of the T2SS and T4P, respectively, in UTI89.

UTI89/pYbcLUTI ybcL::cat as described above, at a speed previously determined to pellet OMVs, separating them from the soluble fraction. By Western blotting, YbcLUTI was detected exclusively in the supernatant fraction after ultracentrifugation (Fig.
2B). Taken together, these data indicate that YbcLUTI is released
from the periplasm in soluble form and is not packaged within
OMVs.
Release of YbcLUTI from UPEC and K-12 E. coli is T2SS and
T4P independent. We previously observed that YbcLUTI suppressed transuroepithelial PMN migration when episomally expressed in nonpathogenic E. coli strain MG1655 (9). As YbcLUTI
was unable to influence PMN migration from within the bacterial
periplasm (9), we hypothesized that the mode of release was conserved between uropathogenic and nonpathogenic E. coli strains.
To test this hypothesis, 5637 cells were infected with either UTI89
or MG1655 episomally expressing YbcLUTI for 1 h, and the supernatant and 5637 cell lysate were filter sterilized, TCA precipitated,
and probed by Western blotting. As with UTI89/pYbcLUTI,
YbcLUTI was detected in both the supernatant and 5637 cell lysate
during infection with MG1655/pYbcLUTI (Fig. 3A). These data
suggest that YbcLUTI release from the periplasm is mechanistically
conserved between these strains and does not require additional
UPEC-specific factors.
We next focused on canonical secretion systems encoded by
both UTI89 and MG1655 that would be capable of translocating
periplasmic substrates. To investigate a role for the T2SS in release
of YbcLUTI from the periplasm, we deleted yheF, which encodes
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FIG 3 T2SS and T4P are dispensable for YbcLUTI release from UPEC and E.

the outer membrane-localized secretin essential for T2SS function. As the T4P is evolutionarily related to the T2SS, we generated
a separate deletion of hofQ, the gene that encodes the T4P secretin.
The localization pattern of YbcLUTI, when episomally expressed in
wild-type UTI89, UTI89 yheF::cat, or UTI89 hofQ::cat, was assessed upon infection of 5637 cells as described above. Similar
levels of YbcLUTI were detected in the supernatant and 5637 cell
lysate irrespective of these mutations (Fig. 3B). These data indicate
that neither the T2SS nor the T4P encoded by UTI89 is responsible
for delivering YbcLUTI to the extracellular milieu. Furthermore, an
isogenic strain lacking expression of flgH, which encodes the secretin of the flagellar biosynthesis machinery, exhibited similar
YbcLUTI localization (data not shown).
YbcL is released into the supernatant in a dose-, time-, and
epithelial cell-dependent manner. As the canonical secretion systems encoded by UPEC appeared to be dispensable for delivering
periplasmic YbcLUTI to the extracellular space, we further characterized the parameters of YbcLUTI release using a quantitative in
vitro assay based on the enzyme activity of ␤-lactamase (TEM-1).
With E. coli expressing a translational fusion between full-length
YbcLUTI and the mature form of TEM-1 (denoted YbcL::TEM-1),
the level of ␤-lactamase activity in the supernatant reflects the
amount of YbcL::TEM-1 liberated. Of note, episomal expression
of YbcL::TEM-1 complemented the phenotype of UTI89 ⌬ybcL in
the transuroepithelial PMN migration assay (data not shown).
Cultured 5637 cells in 6-well plates were infected with UTI89/
pYbcL::TEM-1 ⌬ybcL, and cleared supernatants were assayed in a
96-well plate after addition of the ␤-lactamase substrate CCF2.
When 5637 cells were infected with UTI89/pYbcL::TEM-1 ⌬ybcL
after overnight induction with various concentrations of IPTG,
the level of ␤-lactamase activity in the supernatant correlated with
the level of IPTG induction (see Fig. S1A in the supplemental
material), demonstrating a relationship between the amount of
YbcL::TEM-1 in the periplasm and the amount released into the
supernatant. When 5637 cells were infected with UTI89/pYbcL::
TEM-1 ⌬ybcL for increasing durations before ␤-lactamase activity
was measured, the level of fluorescence in the supernatant increased with longer incubation (see Fig. S1B in the supplemental
material), suggesting that release of YbcL::TEM-1 from the
periplasm occurs over time.
To investigate release of YbcL::TEM-1 in the presence of alternative eukaryotic cell types, UTI89/pYbcL::TEM-1 ⌬ybcL was incubated in RPMI alone or in the presence of cultured uroepithelial
cells (5637, T24, or UROtsa) for 1 h before the level of YbcL::
TEM-1 in the supernatant was measured as described above. Significantly (3- to 4-fold) higher levels of fluorescence were detected
in supernatant generated in the presence of uroepithelial cells than
in supernatant generated in RPMI alone (Fig. 4A) (P ⬍ 0.05). Of
note, release in response to A549 or HCC827 human lung epithelial lines was similar to that with uroepithelial cells (data not
shown). These results indicate that release of YbcL::TEM-1 from
UTI89 is not constitutive but rather is dependent upon specific
conditions.
To investigate extracellular release of YbcL::TEM-1 in the presence of professional phagocytes, 106 PMN were infected with
UTI89/pYbcL::TEM-1 ⌬ybcL for 1 h before ␤-lactamase activity in
the cleared supernatant was quantified. With these experimental
parameters, no ␤-lactamase activity was detected in the supernatant (data not shown). However, previous results had suggested
that the level of YbcLUTI in the supernatant during infection of
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PMN was low (9). In a further attempt to detect YbcL::TEM-1 in
the supernatant, 107 5637 cells or PMN were infected with UTI89/
pYbcL::TEM-1 ⌬ybcL for 1 h. The supernatants were filter sterilized and concentrated 10-fold using centrifugal filtration, and
␤-lactamase activity was measured. Under this modified protocol,
YbcL::TEM-1 was detectable in the supernatant during infection
of PMN, though the level was markedly lower than that observed
during infection of 107 5637 cells (Fig. 4B) (P ⬍ 0.0001). In agreement with these findings, about 7-fold less YbcL was detected in
the supernatant during infection of PMN than during infection of
5637 cells by Western blotting (data not shown). Of note, addition
of protease inhibitors did not alter detection of YbcL (data not
shown), indicating that measured extracellular levels of the target
protein were not lowered by PMN-derived protease digestion.
Taken together, these data demonstrate that extracellular release
of YbcL from the periplasm occurs in a dose-, time-, and epithelial
cell-dependent manner.
UPEC proximity to bladder epithelial cells augments YbcLUTI
release. We next explored the uroepithelial cell-dependent in-
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FIG 4 Release of YbcLUTI is uroepithelial cell dependent. Cultured epithelial
cells in 6-well plates were infected with UTI89/pYbcL::TEM-1 ⌬ybcL for 1 h
unless otherwise indicated. The supernatant was cleared, aliquots were loaded
into a 96-well plate, and the fluorescent ␤-lactamase substrate CCF2 was added
to each well. After 1 h of incubation, fluorescence was measured and is represented as a ratio of 447 to 520 nm. Background fluorescence from medium is
indicated by the dashed line. (A) Significantly more ␤-lactamase activity was
detected in the supernatant after infection of 5637, T24, or UROtsa cells than
after incubation in RPMI (*, P ⬍ 0.05). (B) Supernatant generated from infection of 5637 cells or PMN in 15-cm dishes with UTI89/pYbcL::TEM-1
⌬ybcL was sterilized and concentrated 10-fold, and ␤-lactamase activity was
determined as described above. Significantly more ␤-lactamase activity was
detected in the supernatant after infection of 5637 cells than after infection of
PMN (*, P ⬍ 0.0001).

crease in YbcL::TEM-1 release during UPEC infection. We
employed a UPEC mutant (UTI89 fimH::kan) defective in the
production of type 1 pili, surface appendages that mediate mannose-dependent binding and invasion of bladder epithelial cells
(26–28). Cultured 5637 cells in 6-well plates were infected with
UTI89/pYbcLUTI or UTI89/pYbcLUTI fimH::kan for 1 h before the
supernatant and 5637 cell lysate were sterilized, TCA precipitated,
and probed by Western blotting. Infection with the ⌬fimH strain
resulted in substantially less YbcLUTI detected in the cell lysate
(⬃10% of the wild-type level) (see Fig. S2 in the supplemental
material), confirming that type 1 pili are a major determinant of
UPEC internalization into these cells. Of more interest, lower levels of YbcLUTI were also observed in the ⌬fimH supernatants
(⬃70% of the wild-type level) (see Fig. S2 in the supplemental
material). Further, supernatant fluorescence after infection of
5637 cells with UTI89/pYbcL::TEM-1 ⌬ybcL was diminished by
27% upon addition of mannose (data not shown). These data
support the hypothesis that though contact is not strictly required,
proximity of UPEC to bladder epithelial cells augments extracellular YbcLUTI release.
To further test this hypothesis, Transwell inserts with 0.4-m
pores were employed to spatially separate the bacterial inoculum
from the 5637 cells, while allowing passive diffusion of small molecules. UTI89/pYbcLUTI ybcL::cat was applied directly to the 5637
cells or to the upper reservoir of Transwell inserts. After 1 h of
incubation, the supernatants from both the upper and lower reservoirs and the 5637 cell lysate were processed for Western blotting as described above. In the presence of a physical barrier separating the bacterial inoculum from the 5637 cells, very little
YbcLUTI was detected in the supernatant, and YbcLUTI was absent
from the cell lysate (Fig. 5A).
To confirm these observations, we employed the ␤-lactamase
reporter, using UTI89/pYbcL::TEM-1 ⌬ybcL as the bacterial inoculum, in conjunction with the 0.4-m Transwell inserts. After 1 h
of incubation, the supernatants in the upper and lower reservoirs
were pooled and cleared, and ␤-lactamase activity was measured
as described above. In the absence of Transwell inserts, significantly more fluorescence was detected in the supernatant after
infection of 5637 cells than after incubation in DPBS (Fig. 5B)
(P ⬍ 0.0005), consistent with previous observations. Interposition of the Transwell insert between the bacterial inoculum and
the 5637 cells significantly decreased the fluorescence detected in
the supernatant (Fig. 5B) (P ⬍ 0.005). Taken together, these data
demonstrate that proximity between UPEC and bladder epithelial
cells, augmented by type 1 pili, favors YbcLUTI release from the
periplasm.
Despite the presence of Transwell inserts, significantly more
fluorescence was detected in the supernatant after infection of
5637 cells than after incubation in DPBS alone (Fig. 5B) (P ⬍
0.05), suggesting that soluble factors produced by 5637 cells stimulate some YbcL::TEM-1 release. To address this hypothesis,
UTI89/pYbcL::TEM-1 ⌬ybcL was incubated in RPMI in the presence or absence of 5637 cells for 1 h or in conditioned medium
that had been generated by incubating 5637 cells in RPMI for 1 h.
The level of supernatant ␤-lactamase activity observed upon incubation in conditioned medium was significantly greater than
that observed in RPMI (P ⬍ 0.0001), though significantly less than
that observed in the presence of 5637 cells (Fig. 5C) (P ⬍ 0.05). Of
note, inclusion of E. coli (uropathogenic or nonpathogenic) during generation of the conditioned medium did not alter its effect
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FIG 5 Release of YbcLUTI is augmented by proximity to bladder epithelial
cells. 5637 cells were infected with UTI89/pYbcLUTI ybcL::cat (A) or UTI89/
pYbcL::TEM-1 ⌬ybcL (B and C) for 1 h. (A) The supernatant and 5637 cell
lysate were filter sterilized, TCA precipitated, and probed by Western blotting.
(B and C) ␤-Lactamase activity in cleared supernatant was measured using
CCF2 as described for Fig. 4. Less YbcLUTI was detected in the supernatant
when a Transwell insert (TW) physically separated the bacterial inoculum
from the 5637 cells (A and B) or when conditioned medium (CM) was used
(C) (*, P ⬍ 0.05). Boiling of the conditioned medium (CM-B) did not significantly alter YbcLUTI release (C).

on YbcL::TEM-1 release (data not shown). Finally, similar levels
of fluorescence were detected when the conditioned medium was
boiled before addition of the bacterial inoculum (Fig. 5C). These
data suggest that the soluble factors associated with YbcL::TEM-1
release are host cell derived and largely heat stable.
Bacterial death occurs during infection of bladder epithelial
cells. The canonical secretion systems appeared to be dispensable
for YbcLUTI release from the periplasm during UPEC infection of
bladder epithelial cells. Given that a few E. coli-encoded proteins
(e.g., Shiga toxin and colicin) reach the extracellular milieu exclu-
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5637 cells were infected with UPEC strains expressing the indicated proteins.
After 0 or 60 min, the supernatant was sterilized, TCA precipitated, and probed
by Western blotting. A portion of the bacterial inoculum (input) is also shown.
(B) 5637 cells were mock infected or infected with UTI89 for 0 or 60 min before
the supernatant was sterilized, DNA was precipitated with isopropanol, and
PCR was conducted using UTI89-specific primers. PCRs serving as negative
(⫺) and positive (⫹) controls contained water and UTI89 genomic DNA,
respectively, as the template. Bacterial periplasmic (YbcL, SurA, and Skp) and
cytoplasmic (GroEL and GFP) proteins (A) and bacterial DNA (B) were detected in the supernatant after infection of 5637 cells. (C) UTI89 was incubated
in the presence or absence of 5637 cells for 1 h. Bacteria were fixed to coverslips,
stained for membrane integrity, and imaged and enumerated by fluorescence
microscopy. Significantly more dead bacteria exhibiting severely compromised membranes were observed after infection of 5637 cells than after incubation in RPMI (P ⬍ 0.05).

sively via bacterial death (14, 15), we tested the hypothesis that
YbcLUTI is liberated from the UPEC periplasm in an analogous
manner. First, 5637 cells were infected with UTI89/pYbcLUTI
ybcL::cat, UTI89/pSurA surA::kan, UTI89/pSkp skp::tet, UTI89, or
UTI89 pcomGFP. At 0 and 60 min, supernatants were filter sterilized, TCA precipitated, and probed by Western blotting. To ensure that intracellular proteins detected in the supernatant would
not represent contamination from the overnight bacterial culture,
each bacterial inoculum was washed repeatedly in PBS before infection of the 5637 cells. Accordingly, very little of the periplasmic
proteins YbcL, SurA, and Skp and the cytoplasmic proteins GroEL
and GFP were detected in the supernatant at time zero (Fig. 6A).
In contrast, these intracellular proteins were readily detected in
the supernatant after 60 min (Fig. 6A).
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FIG 6 UPEC viability decreases in the presence of bladder epithelial cells. (A)
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DISCUSSION

The present study furthers our understanding of the mechanism
by which UPEC-encoded YbcL is liberated from the bacterial
periplasm and influences the innate immune response in the bladder. Suppression of PMN migration by purified YbcLUTI required
the presence of bladder epithelial cells. YbcLUTI was released from
the periplasm in soluble form, though independent of the T2SS
and T4P conserved in nonpathogenic and uropathogenic E. coli.
Liberation of YbcLUTI from the periplasm occurred specifically in
response to uroepithelial cells and was maximal when UPEC and
bladder epithelial cells were in close proximity. Lastly, UPEC
death upon exposure to bladder epithelial cells implicates bacterial lysis as the mechanism by which YbcLUTI is released from the
periplasm.
As purified YbcLUTI had no effect on PMN migration in the
absence of bladder epithelial cells, we conclude that YbcLUTI does
not inhibit PMN chemotaxis directly. These data suggest that the
site of action of YbcLUTI is the uroepithelium, though purified
YbcLUTI was detected solely in the supernatant and not in the 5637
cell lysate. Given the low concentration of YbcLUTI sufficient to
suppress PMN migration (9), it is possible that the amount of
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purified protein associated with the 5637 cell lysate was too low to
detect by Western blotting, even when larger dishes were used.
When UPEC was physically separated from bladder epithelial
cells, YbcLUTI was not detected in 5637 cell lysates, further demonstrating that bacterial binding or internalization is required for
YbcLUTI to reach the cell interior. YbcLUTI was released by UPEC
in soluble form rather than as OMV cargo, and a mechanism by
which YbcLUTI could traverse the epithelial membrane in the absence of bacterial internalization is not obvious. Taken together,
these data support a model in which YbcLUTI acts on uroepithelial
cells from the extracellular milieu.
The specificity of YbcLUTI release during UPEC infection of
uroepithelial cells also supports a model in which the bladder
epithelium, rather than PMN, is the site of YbcLUTI activity. The
spatial relationship between the bacterial inoculum and host cells
influences the magnitude of YbcLUTI release from the periplasm.
Supernatant YbcLUTI levels were lower when close association between UPEC and bladder epithelial cells was limited through mutation of type 1 pili, addition of mannose, interposition of a physical barrier, or use of conditioned medium, indicating that
proximity augments YbcLUTI release. While the component(s) of
the conditioned medium associated with YbcL::TEM-1 release appears to be largely heat stable and constitutively expressed by 5637
cells, additional work is required to identify this molecule(s). One
explanation for these observations is that microenvironments at
the bladder epithelial surface, where the local concentration of
molecules secreted by 5637 cells would be highest, are responsible
for the augmented YbcLUTI release. However, it is also possible
that constituents of the bladder epithelial surface contribute to
release of YbcLUTI from the periplasm.
Our interrogation of conserved secretion systems demonstrated that YbcLUTI release is independent of the T2SS and T4P.
We have not generated a UPEC mutant deficient in both systems,
as it is unlikely that the T2SS and T4P function redundantly to
secrete YbcLUTI. Though autotransporters contribute to UPEC
pathogenesis (29, 30), it is unlikely that YbcLUTI belongs to the
T5SS family given the lack of homology (31). Though an as-yetunidentified secretion system could be responsible for mediating
YbcLUTI secretion, our subsequent experiments implicated bacterial death as the mechanism by which YbcLUTI is liberated from
the bacterial cell, a novel mode of delivery for a UPEC exoprotein.
First, multiple bacterial intracellular proteins and DNA were detected in supernatants overlying UPEC-infected bladder epithelial
cells. While secretion systems exist to deliver cytoplasmic and
periplasmic proteins as well as bacterial DNA to the extracellular
space, it is unlikely that the coordinated activity of multiple such
systems is responsible for the simultaneous detection of all these
molecules in the supernatant. Second, bacterial death was substantially augmented upon exposure to bladder epithelial cells.
Our initial efforts to detect bacterial death by plating for survival
revealed an overall increase in CFU, reflecting interval bacterial
growth (M. Lau and D. Hunstad, unpublished data). Using a fluorescence-based approach, significantly more bacteria with severely compromised membranes (representing a prelytic state)
were observed upon UPEC exposure to bladder epithelial cells,
correlating with increased release of YbcLUTI. Future work will
specify whether the presence of bladder epithelial cells and derived
molecules provokes this death via a bacterial mechanism (e.g., a
toxin-antitoxin system or bacteriophage-mediated lysis) or via a
eukaryotic mechanism (e.g., antimicrobial peptides).
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In addition to intracellular proteins, we also probed the supernatant for bacterial DNA after infection of 5637 cells with wildtype UTI89. At selected time points, the supernatant was filter
sterilized, DNA was precipitated using isopropanol, and PCR (using primers complementary to the UTI89 chromosomal ybcL allele) was conducted using an equivalent volume of each sample as
the template. The rounds of amplification were minimized so that
the intensity of the resulting amplicon would be proportional
to the amount of template DNA. As with the protein detection
described above, the bacterial inoculum was washed repeatedly in
PBS before use. While a faint amplicon was generated when precipitated DNA from supernatant processed at time zero was used
as the template, the amplicon generated after 60 min infection was
greater in intensity, indicating a higher concentration of template
DNA (Fig. 6B). No amplicon was generated when precipitated
DNA from the supernatant of mock-infected 5637 cells was used
as the template (Fig. 6B). The presence of bacterial DNA and intracellular proteins in the supernatant under conditions shown to
stimulate release of YbcLUTI is consistent with a model in which
bacterial lysis mediates this release.
To quantify bacterial death directly, we employed fluorescence
microscopy after bacterial staining with a viability kit to visualize
and enumerate bacteria with intact membranes (live; green) versus bacteria with severely compromised membranes (dead; red).
UTI89 was incubated in RPMI in the presence or absence of 5637
cells, conditions shown to stimulate significantly different levels of
YbcLUTI release. After 1 h of incubation in RPMI, 2.48% (⫾0.57%
[SEM]) of the total bacteria were dead (Fig. 6C). However, the
percentage of dead bacteria isolated from the medium increased
approximately 5.6-fold to 13.8% (⫾3.63%) after 1 h of incubation
in the presence of 5637 cells (Fig. 6C) (P ⬍ 0.05). Of note, only
very rare “ghosts” (bacterial remnants not containing DNA) were
evident when a blue-fluorescent antibody combination against
bacterial envelope components was included (data not shown).
The significant increase in bacteria with severely compromised
membranes upon exposure to uroepithelial cells further implicates bacterial death as the mechanism by which YbcLUTI is released into the extracellular milieu.
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Our studies contribute to a model of the early host-pathogen
interactions occurring upon introduction of UPEC into the mammalian bladder. The observed proximity-dependent increase in
YbcLUTI release suggests that bacteria nearest the uroepithelial
surface are the minority that undergo lysis. Given the potency of
YbcLUTI in suppressing PMN migration (9), lysis of very few bacteria at the epithelial surface would likely release a sufficient
amount of YbcLUTI to exert a local effect on an epithelium-derived
target, either secreted or present in the apical membrane. Spatially
controlled release of YbcLUTI at the epithelial surface would maximize the probability of target binding and may explain how a low
concentration of YbcLUTI is sufficient to suppress PMN migration
despite the potential for diffusion into the bladder lumen. Though
UPEC lysis would likely release bacterial products capable of activating host proinflammatory signaling, UPEC also encodes effectors (e.g., HlyA and TcpC) that block these signaling cascades (32,
33). Liberated YbcLUTI would inhibit early migration of PMN into
the bladder lumen, extending a critical interval in which surviving
UPEC can invade the bladder epithelium in the absence of phagocyte pressure. As shown in multiple studies, accessing the intracellular niche protects UPEC from the PMN that ultimately arrive
(34, 35), facilitating the development of the intracellular bacterial
community that is critical to the propagation of infection.
Release of YbcLUTI during UPEC death represents an example
of bacterial altruism, a type of cooperation where some bacteria in
a population benefit, directly or indirectly, at a cost to others (36).
Altruism has been described for other bacterial pathogens and is
proposed to arise when the bacterial population is clonal, the infectious dose is small, and the benefit is significant (36–39), conditions that likely characterize UPEC as it colonizes the human
bladder. YbcLUTI activity may therefore enable a very small (and
otherwise insufficient) UPEC inoculum to establish the foothold
required to initiate cystitis. A more detailed understanding of the
molecular target and function of YbcLUTI and contemporaneously
expressed UPEC effectors may illuminate strategies for prevention
of symptomatic infection in susceptible host populations.
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